The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank
Open accessAbstract
Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th–75th percentile 7.6–74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10–1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race—median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar—hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44–1.56) and 1.16 (95% CI, 1.05–1.27), respectively. Conclusions: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [189]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Cited by
Sorted by citations
Items 301–400 of 573
Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting
Bundgaard, J. S., Rand, S. A., Stender, S., Svendsen, J. H., Lundegaard, P. R., Erikstrup, C., Ahlberg, G., Frikke-Schmidt, R. F. S., Dyrskjøt, L., Larsen, O. H., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120754 · Cited by 4
Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes
Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230601155001 · Cited by 5
Afanasieva, O. I., Tyurina, A. V., Владиславович, Е. М., Андреевна, Р. О., Александровна, К. Е., & Pokrovsky, S. N. (2023) · Diseases · doi:10.3390/diseases11040145 · Cited by 4
Šuran, D., Kanič, V., Kokol, P., Završnik, T., Verhnjak, F., Žlahtič, B., Sinkovič, A., & Naji, F. H. (2024) · Diagnostics · doi:10.3390/diagnostics14232757 · Cited by 4
Липопротеин(а): новые подходы в оценке риска и его управления
Исламовна, Х. З., & Коновалов, Г. А. (2025) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2025.01.0001 · Cited by 4
Lipoprotein (a) Distribution in Aortic Stenosis Patients
Durr, M.-R. R., Burwash, I. G., LAU, L. S. W., Alfraidi, H., Mulloy, A. J., Tavoosi, A., Arangalage, D., Chan, V., Lakhani, M., Aljamaan, A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101662 · Cited by 4
Konovalov, G. A., Исламовна, Х. З., Mukhtarov, M. B., Averkiev, V. L., Korneeva, O. N., Kalacheva, O. S., & Rabicheva, V. S. (2025) · Kardiologiia · doi:10.18087/cardio.2025.4.n2866 · Cited by 4
Lipoprotein(a) as a predictor of mortality in hospitalised patients with ischaemic heart disease
Loh, W. J., Koh, X. H., Yeo, C., Ruan, X., Chai, S. C., Chow, W., Aw, T. C., Heng, C., & Foo, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1541712 · Cited by 4
Nasoufidou, A., Glava, A., Mavridou, M., Stachteas, P., Karagiannidis, E., Patoulias, D., Kassimis, G., Fragakis, N., & Kavga, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176018 · Cited by 4
Deo, N., Siddiqui, H., Peppercorn, K., Madani, G., Rutherford-Blyth, A., Rutledge, M. T., Williams, M. J. A., McCormick, S. P. A., & Redpath, G. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100889 · Cited by 4
Legget, M. E., Earle, N. J., Poppe, K., Bradbury, K. E., Pilbrow, A. P., Logue, G., Choi, Y. C., Devlin, G., Gladding, P. A., Grey, C., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120516 · Cited by 4
Breitbart, P., Liebetrau, C., Grün, D., Eggebrecht, H., Lindhoff‐Last, E., Westermann, D., Voigtländer, T., & Schmermund, A. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02770-w · Cited by 4
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 4
Lipoprotein(a) in clinical practice: What clinicians need to know
Al-Dalakta, A., Cho, L. S., & Sarraju, A. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.25020 · Cited by 4
Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing
Shah, P., King, S., Trabanino, S., Parsa, S., Chen, T. P., & Rodríguez, F. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01365-0 · Cited by 4
Pelusi, S., Macchi, C., Malvestiti, F., Margarita, S., Matteis, I. D., Periti, G., Rondena, J., Mira, S., Iemma, F., Tranchina, M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03004-z · Cited by 4
Kumbhani, D. J., Gibson, C. M., Kinlay, S., Peterson, E. D., Pollak, A. W., Tamis‐Holland, J. E., & Verheugt, F. W. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.037 · Cited by 5
Bergmann, K., Stefańska, A., Krintus, M., & Sypniewska, G. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.04.010 · Cited by 4
Frequency & factors associated with elevated lipoprotein-a among Ghanaian stroke survivors
Gyabaah, S., Adu‐Boakye, Y., Sarfo‐Kantanka, O., Gyan, K. F., Kokuro, C., Agyei, M. K., Akassi, J., Tawiah, P., Norman, B., Ovbiagele, B. I., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122839 · Cited by 4
Impaired endogenous fibrinolysis status: a potential prognostic predictor in ischemic stroke
Yang, C. H. E. N., Gue, Y. X., McDowell, G., Gorog, D. A., & Lip, G. Y. H. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09133-x · Cited by 4
Capra, M. E., Biasucci, G., Banderali, G., & Pederiva, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168817 · Cited by 4
Genetic Drivers of Cardiovascular Risk among South Asian Adults
Gami, A., Bhattacharya, R., Natarajan, P., & Patel, J. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00741-w · Cited by 4
Saraiva, M., Garcez, J. B., da Silva, B. T., Ferreira, I. P., Oliveira, J. C., & Palma, I. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02433-9 · Cited by 4
Arnold, N., Goßling, A., Bay, B., Weimann, J., Blaum, C. M., Brunner, F. J., Ferrario, M. M., Brambilla, P., Cesana, G., Leoni, V., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf340 · Cited by 4
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome
Steg, P. G., Szarek, M. J., Valgimigli, M., Islam, M. S., Zeiher, A. M., Bhatt, D. L., Bittner, V., Chiang, C., Díaz, R., Goodman, S. G., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.018 · Cited by 4
Patel, J., Bhatia, H. S., & Spitz, J. A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100939 · Cited by 4
Huang, L., Li, Y., Xu, X., Chen, W., Zhang, Z., Sun, L., & Gao, X. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.06.004 · Cited by 3
Cardiovascular Disease Burden among African Migrants
Meeks, K. A. C., & Agyemang, C. O. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01307-w · Cited by 3
Mojahedi, A., Chen, O., Skopicki, H. A., Rahman, T., & Sadeghian, A. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm42784 · Cited by 3
Outcomes after coronary angiography in individuals with elevated lipoprotein(a)
Supriami, K., Faaborg-Andersen, C. C., Cho, S. M. J., Tello-Ayala, J. R., Abou-Karam, R., Pomerantsev, E. V., Viscosi, V., Haidermota, S., Hornsby, W., Natarajan, P., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf690 · Cited by 3
Self-citationDelialis, D., Manifava, P., Giannakopoulou, S., Konstantaki, C., Athanasopoulos, S., Zervas, G., Nastatos, P., Mavraganis, G., Sopova, K., Dimopoulou, M., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.016 · Cited by 3
Lipoprotein(a) Is Associated With Increased Risk of Abdominal Aortic Aneurysm
Sharma, P., Judy, R., Yuan, S., Gellatly, C., Saxby, K. L., Rader, D. J., Bown, M. J., Levin, M. G., & Damrauer, S. M. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101457 · Cited by 3
Lipoprotein(a): the neglected risk factor in cardiovascular health
Irvine, A., Watt, J., Kurth, M. J., Laura, M., Clark-McKellar, J., Keteepe‐Arachi, T., Lamont, J. V., Dowey, L. R. C., Fitzgerald, P., & Ruddock, M. W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1710557 · Cited by 3
Jigoranu, A. R., Mitu, O., Oancea, A. F., Miftode, R.-Ş., Buburuz, A. M., Bazyani, A., Gavril, R. S., Stamate, T.-C., Adam, C. A., Miftode, I.-L., et al. (2026) · Medicina · doi:10.3390/medicina62020297 · Cited by 3
Association of lipoprotein(a) with ASCVD risk in women by menopausal status: the UK Biobank
Reyes, M. P., Razavi, A. C., & Bhatia, H. S. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101465 · Cited by 3
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Ferdinand, K. C., Rodríguez, F., Amraotkar, A. R., Venkataraman, S. T., Ayaz, I., Antequera, O., Cao, H., Zhu, W., Wang, J., & Shapiro, M. D. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101467 · Cited by 4
González-Aguado, N., Larrubia-Valle, J. I., Franco-Hita, R., Piserra‐López, A., Expósito, A. D., Garcia-Ruiz, V., Puyol-Ruiz, F., Barquero-Alegre, O., Chinchilla, F. C., Domínguez-Franco, A. J., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051938 · Cited by 5
Nishiyama, K., Nishihira, K., Nakai, M., Baba, K., Takamatsu, M., Honda, Y., Yamamoto, K., Nishino, S., Kadooka, K., Kudo, T., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-0889 · Cited by 3
Srikulmontri, T., Pantarote, S., Kulthamrongsri, N., Wattanachayakul, P., Vutthikraivit, W., & Amanullah, A. M. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2643431 · Cited by 3
Kazibwe, R., Schaich, C. L., Kingsley, J., Chevli, P. A., Mirzai, S., Rikhi, R. R., Masrouri, S., Slipczuk, L. N., & Shapiro, M. D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag221 · Cited by 3
Lim, L. C., Al-Jarshawi, M., Chew, N. W., Shepherd, T. A., Partington, R. J., Sabouret, P. F., Al-Alwany, A. A., Ray, K. K., & Mamas, M. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.063 · Cited by 3
McParland, J., Rikhi, R. R., Bhatia, H. S., Razavi, A. C., Chevli, P. A., Mirzai, S., Spitz, J. A., Sharma, G. V., Khan, S., Slipczuk, L. N., et al. (2026) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2026.05.005 · Cited by 3
Lin, Z., He, J., Song, C., Zhang, R., Yuan, S., Bian, X., & Dou, K. (2024) · Angiology · doi:10.1177/00033197241255414 · Cited by 3
Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting
Jeevanathan, J., Blom, S., Olsén, T., Holven, K. B., Arnesen, E., Trydal, T., Nordestgaard, B. G., Sovershaev, M., Chen, Y., Retterstøl, K., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100726 · Cited by 3
Rybicka, M., Seroka, A., Obrębski, M., Chwiejczak, J., Górny, A., Kościan, J., Młynarska, J., Szczerkowska, K., Wójcik, A., & Mitkowska, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.212 · Cited by 3
Loewenstein, I., Lichtenstein, D., Goldiner, I., Ben‐Shoshan, J., Halkin, A., Konigstein, M., Banai, S., Arbel, Y., Finkelstein, A., & Steinvil, A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101264 · Cited by 3
Looking for lipoprotein(a) in youngsters: a call to action
Bilato, C., Zuin, M., & Rigatelli, G. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001717 · Cited by 3
Renkens, M. P. L., Tsai, T., Revaiah, P. C., Kageyama, S., Reiber, J. H. C., de Winter, R. J., Grundeken, M. J., Nurmohamed, N. S., Stroes, E. S. G., Garg, S., et al. (2025) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2025.07.003 · Cited by 3
Passey, S., Jha, J., Chanda, A., Pillai, A. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001017 · Cited by 3
Mahajan, K., Himral, S., Sharma, J. B., Sandal, S., Bhatia, T., Thakur, R., Patel, I., Mohite, K., Chandel, P., & Bhutani, J. (2025) · Cureus · doi:10.7759/cureus.90747 · Cited by 3
Lipoprotein(a) and Vascular Redox State in Patients With Advanced Coronary Atherosclerosis
Polkinghorne, M., Badi, I., Baragetti, A., Chauhan, J. S., Xie, C., Wahome, E., Akoumianakis, I., Foran, D., Patel, P., de Araujo, E., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322924 · Cited by 5
Xue, R., Liu, J., Wang, H., Wu, X., Ma, M., Zhu, Y., Wen, D., & Zheng, M. (2025) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.125.018413 · Cited by 3
Lp(a) in the Horizon of Diagnostics and Therapy
Formisano, P., Vianello, E., Dozio, E., Tacchini, L., Romani, L. R., Frati, L., Curcio, F., Bellet, M. M., & Corsi-Romanelli, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010290 · Cited by 3
Emerging therapies targeting lipoprotein(a): Pharmacologic advances and future directions
Perez, A. D., Simpson, R. J., Komé, A. M., & Lopez, S. T. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103695 · Cited by 3
Changes of lipoprotein(a) levels with endogenous steroid hormones
Tessitore, E., Dobretz, K., Dhayat, N. A., Kern, I., Ponte, B., Pruijm, M. T., Ackermann, D., Estoppey, S., Burnier, M., Martin, P., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13699 · Cited by 3
High levels of lipoprotein(a) – assessment and treatment
Svilaas, T., Klemsdal, T. O., Bogsrud, M. P., Græsdal, A., Vesterbekkmo, E. K., Asprusten, E. A., Langslet, G., & Retterstøl, K. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.21.0800 · Cited by 3
Šuran, D., Završnik, T., Kokol, P., Kokol, M., Sinkovič, A., Naji, F. H., Završnik, J., Vošner, H. B., & Kanič, V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093220 · Cited by 3
Jung, H. W., Kim, C., Hong, S. P., Bae, H., Choi, J. Y., Ryu, J. K., Lee, J., Lee, K., Han, K., Yang, D., et al. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14715 · Cited by 3
Wang, Z., & Li, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01926-9 · Cited by 3
Genetic Characteristics Contributing to Lipoprotein(a) Levels in the Japanese Population
Yamagami, K., Tada, H., Sato, T. K., Nomura, A., Sakata, K., Usui, S., Kawashiri, M., Tajima, A., & Takamura, M. (2023) · Journal of Coronary Artery Disease · doi:10.7793/jcad.29.23-00015 · Cited by 3
Jennings, C. S., Kenny, E., Bacquer, D. D., Cegla, J., Ray, K. K., Corry, J.-P., Adamska, A., Kotseva, K., McEvoy, J. W., Noone, C., et al. (2025) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvaf174 · Cited by 3
Clouet-Foraison, N., Vaisar, T., & Marcovina, S. M. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_19 · Cited by 3
HDL-C in Black Adults for ASCVD Risk Calculation
Ferdinand, K. C. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.007 · Cited by 3
Thrombosis and Anticoagulation in East Asian Patients With COVID-19
Ki, Y., & Jeong, Y. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.10.006 · Cited by 3
The mysterious lipoprotein(a): moving towards further understanding of its atherogenic role
Rocha, V. Z., & Santos, R. D. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae321 · Cited by 3
Biobanks in cardiovascular disease research
Гусакова, А. М., Kravchenko, E. S., Суслова, Т. Е., Popov, S. V., & Boshchenko, A. A. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-4170 · Cited by 3
Brix, G. S., Rasmussen, L. D., Rohde, P. D., Nissen, L., Nyegaard, M., O’Donoghue, M., Bøttcher, M., & Winther, S. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.01.001 · Cited by 2
Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory
Velilla, T. A., Fernández‐Prendes, C., Amigó, N., Calmarza, P., Anguila, S. C., Estébanez, B. C., Castro, M. J. C., Ceacero-Marín, D., Martínez, I. G., Palencia, M. M., et al. (2025) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2025-0034 · Cited by 2
Sosnowska, B., Bytyçi, I., Lewek, J., Bielecka-Dabrowa, A. M., Burzyńska, M., Jankowski, P., Chudzik, M., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/209946 · Cited by 3
Ward, A., Kron, B., Lozama, A., Sandhu, A. T., Khandelwal, A., Rodríguez, F., Dash, R., & Nallamshetty, S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102253 · Cited by 2
Sanchis‐Gomar, F., & Lippi, G. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2768-2477 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0388 · Cited by 2
Coerkamp, C. F., Verpalen, V. A., Bouhbouh, K., Renkens, M. P. L., Witte, L. S., Kaiser, Y., Kuipers, R. S., Chamuleau, S. A. J., Knaapen, P., Delewi, R., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102542 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S.-G., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.2 · Cited by 2
Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)
Botros, M., Tiji, M., & Lange, R. A. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x418596251201142137 · Cited by 2
Xiang, B., Zhang, R., Zhou, Y., Zhang, S., Zhao, Y., Yang, X., & Zhou, X. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag090 · Cited by 2
Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome
González-Aguado, N., Franco-Hita, R., Larrubia-Valle, J. I., Puyol-Ruiz, F., Mezcua, A. R., García‐Pinilla, J. M., Jiménez-Salva, M., Piserra‐López, A., Pavón, F. J., Pérez-Cabeza, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051688 · Cited by 2
Hsu, H., Fan, H., Tsai, M.-C., Lai, C.-J., Hwang, L. C., & Chien, K. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-0847 · Cited by 2
Jiang, Y., Lin, J., Ma, M., Xu, J., Yu, P., & Wang, H. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66159 · Cited by 2
Yamada, T., Tada, H., Ogura, M., Funabashi, S., Yoshida, H., Hiraishi, C., Ebihara, T., Hadano, T., Masaki, T., Takeji, Y., et al. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66185 · Cited by 2
Lipoprotein(a) and residual cardiovascular risk in statin-treated patients
Oftadeh, S.-L., Pütz, A., Jacobsen, M., Balfanz, P., Marx, N., Brandts, J., Müller‐Wieland, D., & Verket, M. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag296 · Cited by 2
Bobrowska, B., Dziewierz, A., Domienik‐Karłowicz, J., Zasada, W., Rajtar-Salwa, R., Rulkiewicz, A., & Siudak, Z. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.026 · Cited by 2
Influence of pseudoxanthoma elasticum on the lipid profile and prognostic implications
Stumpf, M. J., Winkler, T., Siebigteroth, M., Lenzen, A., Weinhold, L., Nickenig, G., Hendig, D., Skowasch, D., Schahab, N., & Schaefer, C. A. (2024) · VASA · doi:10.1024/0301-1526/a001134 · Cited by 2
Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort
Telis, N., Dai, H., Waring, A. A., Kann, D., Wyman, D., White, S., Khuder, B., Tanudjaja, F., Bolze, A., Levy, M. E., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.012 · Cited by 2
Cegla, J., Jennings, C. S., Kenny, E., Bacquer, D. D., Ray, K. K., Corry, J.-P., Adamska, A., Kotseva, K., McEvoy, J. W., Noone, C., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf527 · Cited by 2
Burzyńska, M., Jankowski, P., Babicki, M., Banach, M., & Chudzik, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196713 · Cited by 2
What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?
Tsimikas, S. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e7 · Cited by 2
Zhang, Z., Mo, Y., Li, Y., Pan, Y., Wang, S., Xu, M., Zhou, H., & Liu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359015 · Cited by 2
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery
Patel, S. K., Badross, M. S., Dhingra, N. K., Moroney, M., Casey, J. H., Hassan, S. M. A., Khan, T., Hess, D. A., Koschinsky, M. L., Teoh, H., et al. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.01.013 · Cited by 2
Gelfert, G. G., Grittner, U., Kuhnert, R., Scheidt‐Nave, C., Endres, M., & Nave, A. H. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102015 · Cited by 2
Inflammation and cardiometabolic disease in South Asians: The fire and fire tenders
Balaji, K., Chahil, V., Shakoor, A., Kalra, D., & Vijayaraghavan, K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.068 · Cited by 2
Kalka, C., Lippik, L., Wenzel, F., Hoppe, H., Keo, H. H., Heiß, C., & Diehm, N. (2023) · VASA · doi:10.1024/0301-1526/a001072 · Cited by 2
Lp(a) and inflammation: a new insight into atherosclerosis
Pan, H., Hu, K., Wu, Q., Tu, Y., & Guo, Z. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.247 · Cited by 2
Практическая значимость измерения уровня липопротеида(а) для стратификации риска
Муратович, Н. А., Зафираки, В. К., Кручинова, С. В., О., П. И., & Космачева, Е. Д. (2022) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2022.02.0003 · Cited by 2
Wong, N. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154380 · Cited by 2
The Importance of Apo B and Lipoprotein Little a [Lp(a)]
Alpert, J. S., & Stone, N. J. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.02.025 · Cited by 2
Cesaro, A., Scherillo, G., Michele, G. D., Acerbo, V., Signore, G., Panico, D., Porcelli, G., Scialla, F., Raucci, G., Rotolo, F. P., et al. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.35 · Cited by 1
Afanasieva, O. I., Arefieva, T. I., Tyurina, A. V., Filatova, A. Y., Андреевна, Р. О., Александровна, К. Е., Radyukhina, N. V., Ruleva, N. Y., Владиславович, Е. М., & Pokrovsky, N. S. (2024) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20241901129 · Cited by 1
Lipoprotein(a) as a Predictor of Nonalcoholic Fatty Liver After Pancreatectomy
Abe, K., FUJIOKA, S., Takano, Y., Shirai, Y., Tsunematsu, M., Matsumoto, M., Furukawa, K., Haruki, K., Onda, S., & Ikegami, T. (2024) · Anticancer Research · doi:10.21873/anticanres.17416 · Cited by 1
Metadata
- Authors
- Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V.
- Affiliations
- Broad Institute (US)
- IBM Research - Cambridge (United States) (US)
- Corresponding author
- Khera, Amit V.
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2021-01
- Volume
- 41
- Issue
- 1
- Pages
- 465-474
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC7769893
- OpenAlex
- W3097307979
- Cited by
- 567
- References
- 50
- Citations by year
- 2026: 135 · 2025: 147 · 2024: 110 · 2023: 89 · 2022: 60 · 2021: 25
- FWCI
- 39.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Heart Association (R01 HL128914, 18SFRN34110082)
- Massachusetts General Hospital
- Broad Institute
- Fondation Leducq (K24HL105780, 18SFRN34110082, 1RO1HL092577, T32HL007208, 14CVD01, R01HL128914)
- Medical Research Council (MC_PC_17228)
- National Heart, Lung, and Blood Institute (1RO1HL092577, R01HL128914, K24HL105780, R01HL092577, T32HL007208)
- National Human Genome Research Institute (K08HG010155, 18SFRN34110082)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lipoprotein(a), atherosclerotic cardiovascular disease, incident cardiovascular events, racial differences, risk gradient, primary prevention, secondary prevention, middle-aged adults, UK Biobank
- MeSH terms
- Race Factors, Heart Disease Risk Factors, Adult, Aged, Female, United Kingdom, Humans, Male, Middle Aged, Primary Prevention, Prognosis, Time Factors, Biomarkers, Incidence, Lipoprotein(a), Biological Specimen Banks, Risk Assessment, Atherosclerosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
